EQRx, Inc. Common Stock
EQRX
EQRX: EQRx Inc is a biotechnology company. the company has more than 10 programs in its pipeline, including clinical, preclinical and drug engineering targets for the treatment of oncology and immune-inflammatory conditions. The program includes Aumolertinib, Lerociclib, Sugemalimab, Nofazinlimab, and others.
moreShow EQRX Financials
Recent trades of EQRX by members of U.S. Congress
Recently reported changes by institutional investors
Quarterly net insider trading by EQRX's directors and management
Government lobbying spending instances
-
$10,000 Jul 20, 2022 Issue: Health Issues
-
$30,000 Apr 20, 2022 Issue: Health Issues
-
$30,000 Jan 20, 2022 Issue: Health Issues
-
$30,000 Oct 20, 2021 Issue: Health Issues
-
$30,000 Jul 20, 2021 Issue: Health Issues
-
$30,000 Apr 20, 2021 Issue: Health Issues
-
$30,000 Jan 21, 2021 Issue: Health Issues
-
$30,000 Oct 20, 2020 Issue: Health Issues
-
$30,000 Jul 20, 2020 Issue: Health Issues
-
$40,000 Apr 20, 2020 Issue: Health Issues
-
$30,000 Jan 20, 2020 Issue: Health Issues
New patents grants
Federal grants, loans, and purchases
Followers on EQRX's company Twitter account
Number of mentions of EQRX in WallStreetBets Daily Discussion
Recent insights relating to EQRX
Recent picks made for EQRX stock on CNBC
ETFs with the largest estimated holdings in EQRX
Flights by private jets registered to EQRX